Randomized, double-blind clinical study in order to assess the tolerability and dermatological efficacy of a drug that contains Pycnogenol, which is used to treat Melasma

Medcin Instituto da Pele0 sitesStarted: June 9, 2015Last updated: May 29, 2023

Trial Snapshot

No summary available.

•100 participants; age range 25-65 years old; female; fitzpatrick skin types II and III;
•patients with facial melasma; without any other cutaneous disease; without previous reaction to topical product; the patient should agree with the study-related procedures and the determinated days and time of appointments; Reading; understanding; agreement and signature of patient on the written informed free consent form.

•Pregnancy; lactation; hormonal therapy within the last 4 weeks; use of photosensitizing drug; any melasma treatment in the same time;intensive solar exposure within the last 15 days and during the study; cutaneous marks on the experimental area that might interfere with cutaneous reaction evaluation; use of corticoide until 30 days before the selection and during the study;endocrine dysfunction; use of cosmetic products that might cause any facial irritation , even if it is mild such as exfoliating and antiaging products; other conditions that may be considered by doctors as a reason for disqualification of patient’s participation in the study

Sponsor

Medcin Instituto da Pele